Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

Breast 25Gastrointestinal 14Other hematologic neoplasm 13Head & Neck 5Thoracic 4Lymphoid 4Sarcoma 3Plasma cell 3Gynecologic 3Classical hematology 3Myeloid 2Other neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5744Lung Neoplasms 3716Small Cell Lung Carcinoma 1017Breast Neoplasms 667Neoplasms 616Colorectal Neoplasms 556Melanoma 479Ovarian Neoplasms 434Neoplasm Metastasis 431Pancreatic Neoplasms 386Stomach Neoplasms 332Carcinoma, Renal Cell 311Adenocarcinoma of Lung 308Squamous Cell Carcinoma of Head and Neck 304Head and Neck Neoplasms 293Prostatic Neoplasms 284Mesothelioma, Malignant 281Esophageal Neoplasms 265Mesothelioma 244Colonic Neoplasms 225Brain Neoplasms 216Urinary Bladder Neoplasms 212Triple Negative Breast Neoplasms 209Uterine Cervical Neoplasms 207Endometrial Neoplasms 174Sarcoma 171Carcinoma, Hepatocellular 158NSCLC 134Kidney Neoplasms 127Carcinoma 127

Interventions

Pemetrexed 2durvalumab 1Tretinoin 1Surgical Procedures, Operative 1Paclitaxel 1Observation 1Gemcitabine 1Cisplatin 1Carboplatin 1Bortezomib 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Pathologic Complete Response × Thoracic × Clear all
NCT06694454 2026-05-27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT07586826 2026-05-14

N01-A-PICIT-GT

Peking University People's Hospital

Phase 2 Recruiting
220 enrolled
BreastClassical hematologyGynecologicThoracic

Pathologic Complete Response, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thrombocytopenia, Endometrial Neoplasms

NCT06743555 2026-04-28

SAVED LUNG

Centre hospitalier de l'Université de Montréal (CHUM)

Phase 1 Not yet recruiting
14 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT00343720 2008-03-13

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Millennium Pharmaceuticals, Inc.

Phase 2 Completed
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡